Compare · head to head
Inotiv vs Pacific Biosciences of California
Dead heat overall: both rank 16 on the 360° View.
Inotiv leads on Value (53 vs 40) and Quality (47 vs 29). Pacific Biosciences of California leads on Safety (30 vs 12) and Sentiment (56 vs 49).
Ranks as of 2026-06-12 · 1–100 vs true peers. Higher is better.
| Compare | ||
|---|---|---|
| Profile | ||
| Country | USA | USA |
| Sector | Health Care | Health Care |
| Industry | Life Sciences Tools & Services | Life Sciences Tools & Services |
| Size | Small | Small |
| ISIN | US45783Q1004 | US69404D1081 |
| Last update | 2026-04-02 | 2026-04-02 |
| History | ||
| 360 (V1) since 2023 | ||
| Ranks | ||
| 360 | 16 | 16 |
| Value | 53 | 40 |
| Quality | 47 | 29 |
| Growth | NR | 54 |
| Safety | 12 | 30 |
| Sentiment | 49 | 56 |
| Quality details | ||
| Profitability | 41 | 13 |
| Cash Truth | 53 | 44 |
Inotiv vs Charles River LaboratoriesInotiv vs SchrödingerInotiv vs CertaraInotiv vs Aclaris TherapeuticsAdd a third stock →
Full analyses: Inotiv · Pacific Biosciences of California
Make Sense of the Ranks
Every rank runs 1–100 against true peers. Higher is always better.
360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100